VAS pain
active disease, Pain, pain
DISEASE
Mean (SD) pain at 24 months was 17.3 (25.5) mm in arm 1, 25.6 (28.5) mm in arm 2 and 15.8 (21.0) mm in arm 3 (overall 19.5(25.3)). When comparing pain scores over time per treatment arm, pain decreased significantly in every arm with β -1.37 mm (95% CI -1.73;-1.02) per month. No significant difference was found in pain over 24 months between treatment arms (interaction term treatment arm*time (months) in arm 1 with β (95% CI) 0.13 (-0.36; 0.62) and in arm 2 with β 0.37 (-0.12; 0.86) compared to arm 3). Correction for age and sex yielded similar results. Pain trajectories over time are depicted in Fig. VAS pain outcomes over 24 months in the three treatment arms, based on linear mixed models with random intercept and random slope on unimputed data. Errors bar indicate 95% confidence intervalWhen performing the model for the first three months separately, pain decreased at a similar rate in each treatment group with β(95% CI) -7.82 mm (-11.12; -4.53) per month. Arm 1 compared to arm 3 with β(95% CI) 1.45(-3.14; -6.03) and arm 2 with β(95% CI) 2.33(-2.19; 6.85).Over 24 months, more than 70 percent of patients reached inactive disease [VAS pain active and inactive disease. VAS pain in children with active disease and inactive disease at 12 and 24 months with median and interquartile range. Inactive disease was determined based on adjusted Wallace criteria. At 12 months inactive disease 